Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA

Virology

Volumn 372, Issue 2, 2008, Pages 260-272

  Wyatt, Linda S ^a   Belyakov, Igor M ^b   Earl, Patricia L ^a   Berzofsky, Jay A ^b   Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Mucosal immunity; Recombinant modified vaccinia virus Ankara; Truncated HIV Env

Indexed keywords

AMINO ACID; CD4 ANTIGEN; CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOPLASM; CYTOTOXIC T LYMPHOCYTE; ENVELOPE GENE; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE EXPRESSION; GENETIC STABILITY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INTESTINE; LYMPHOID TISSUE; MEMORY T LYMPHOCYTE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; SPLEEN; VACCINIA VIRUS; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CELL MEMBRANE; CHICK EMBRYO; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, VIRAL; HIV; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MUTATION; T-LYMPHOCYTES, CYTOTOXIC; VACCINIA VIRUS;

MUS; VACCINIA VIRUS ANKARA;

EID: 39449130853     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.10.033     Document Type: Article

References (65)

1. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., and Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74
2. Amara R.R., Smith J.M., Staprans S.I., Montefiori D.C., Villinger F., Altman J.D., O'Neil S.P., Kozyr N.L., Xu Y., Wyatt L.S., Earl P.L., Herndon J.G., McNicholl J.M., McClure H.M., Moss B., and Robinson H.L. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76 (2002) 6138-6146
3. Amara R.R., Villinger F., Staprans S.I., Altman J.D., Montefiori D.C., Kozyr N.L., Xu Y., Wyatt L.S., Earl P.L., Herndon J.G., McClure H.M., Moss B., and Robinson H.L. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J. Virol. 76 (2002) 7625-7631
4. Antoine G., Scheiflinger F., Dorner F., and Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244 (1998) 365-396
5. Ashorn P., Berger E.A., and Moss B. Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of non-primate cells with human cells. J. Virol. 64 (1990) 2149-2156
6. Barouch D.H., Santra S., Kuroda M.J., Schmitz J.E., Plishka R., Buckler-White A., Gaitan A.E., Zin R., Nam J.H., Wyatt L.S., Lifton M.A., Nickerson C.E., Moss B., Montefiori D.C., Hirsch V.M., and Letvin N.L. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 75 (2001) 5151-5158
7. Belyakov I.M., Ahlers J.D., Brandwein B.Y., Earl P., Kelsall B.L., Moss B., Strober W., and Berzofsky J.A. The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Invest. 102 (1998) 2072-2081
8. Belyakov I.M., Derby M.A., Ahlers J.D., Kelsall B.L., Earl P., Moss B., Strober W., and Berzofsky J.A. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 1709-1714
9. Belyakov I.M., Wyatt L.S., Ahlers J.D., Earl P., Pendleton D., Kelsall B.L., Strober W., Moss B., and Berzofsky J.A. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J. Virol. 72 (1998) 8264-8272
10. Belyakov I.M., Moss B., Strober W., and Berzofsky J.A. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4512-4517
11. Belyakov I.M., Ahlers J.D., Clements J.D., Strober W., and Berzofsky J.A. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. J. Immunol. 165 (2000) 6454-6462
12. Belyakov I.M., Hel Z., Kelsall B., Kuznetsov V.A., Ahlers J.D., Nacsa J., Watkins D.I., Allen T.M., Sette A., Altman J., Woodward R., Markham P.D., Clements J.D., Franchini G., Strober W., and Berzofsky J.A. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7 (2001) 1320-1326
13. Belyakov I.M., Wang J., Koka R., Ahlers J.D., Snyder J.T., Tse R., Cox J., Gibbs J.S., Margulies D.H., and Berzofsky J.A. Activating CTL precursors to reveal CTL function without skewing the repertoire by in vitro expansion. Eur.J. Immunol. 31 (2001) 3557-3566
14. Berlioz-Torrent C., Shacklett B.L., Erdtmann L., Delamarre L., Bouchaert I., Sonigo P., Dokhelar M.C., and Benarous R. Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. J. Virol. 73 (1999) 1350-1361
15. Bultmann A., Muranyi W., Seed B., and Haas J. Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression. J. Virol. 75 (2001) 5263-5276
16. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 (1994) 1024-1027
17. Byland R., Vance P.J., Hoxie J.A., and Marsh M. A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein. Mol. Biol. Cell 18 (2007) 414-425
18. Cebere I., Dorrell L., McShane H., Simmons A., McCormack S., Schmidt C., Smith C., Brooks M., Roberts J.E., Darwin S.C., Fast P.E., Conlon C., Rowland-Jones S., McMichael A.J., and Hanke T. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24 (2006) 417-425
19. Chakrabarti L., Emerman M., Tiollais P., and Sonigo P. The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity. J. Virol. 63 (1989) 4395-4403
20. Durbin A., Wyatt L.S., Slew J., Moss B., and Murphy B.R. The immunogenicity and efficacy of intranasally or parenterally adminstered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys. Vaccine 16 (1998) 1324-1330
21. Dzutsev A.H., Belyakov I.M., Isakov D.V., Margulies D.H., and Berzofsky J.A. Avidity of CD8 T cells sharpens immunodominance. Int. Immunol. 19 (2007) 497-507
22. Earl P.L., Hügin A.W., and Moss B. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J. Virol. 64 (1990) 2448-2451
23. Earl P., Koenig S., and Moss B. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J. Virol. 65 (1991) 31-41
24. Earl P.L., Broder C.C., Long D., Lee S.A., Peterson J., Chakrabarti S., Doms R.W., and Moss B. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 68 (1994) 3015-3026
25. Earl P.L., Broder C.C., Doms R.W., and Moss B. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J. Virol. 71 (1997) 2674-2684
26. Earl P.L., Moss B., Wyatt L.S., and Carroll M.W. Generation of recombinant vaccinia viruses. In: Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., and Struhl K. (Eds). Current Protocols in Molecular Biology vol. 2 (1998), Greene Publishing Associates & Wiley Interscience, New York 16.17.1-16.17.19
27. Earl P.L., Wyatt L.S., Montefiori D.C., Bilska M., Woodward R., Markham P.D., Malley J.D., Vogel T.U., Allen T.M., Watkins D.I., Miller N., and Moss B. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric env protein boost in the SHIV rhesus macaque model. Virology 294 (2002) 270-281
28. Edwards T.G., Wyss S., Reeves J.D., Zolla-Pazner S., Hoxie J.A., Doms R.W., and Baribaud F. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J. Virol. 76 (2002) 2683-2691
29. Gorny M.K., Conley A.J., Karwowska S., Buchbinder A., Xu J.Y., Emini E.A., Koenig S., and Zolla-Ppazner S. Neutralization of diverse human immunodeficiency virus type-1 variants by an Anti-V3 human monoclonal antibody. J. Virol. 66 (1992) 7538-7542
30. Haffar O.K., Nakamura G.R., and Berman P.W. The carboxy terminus of human immunodeficiency virus type 1 gp160 limits its proteolytic processing and transport in transfected cell lines. J. Virol. 64 (1990) 3100-3103
31. Harrer E., Bauerle M., Ferstl B., Chaplin P., Petzold B., Mateo L., Handley A., Tzatzaris M., Vollmar J., Bergmann S., Rittmaier M., Eismann K., Muller S., Kalden J.R., Spriewald B., Willbold D., and Harrer T. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir. Ther. 10 (2005) 285-300
32. Hirsch V.M., Edmondson P., Murphey-Corb M., Arbeille B., Johnson P.R., and Mullins J.I. SIV adaptation to human cells. Nature 341 (1989) 573-574
33. Hirsch V.M., Fuerst T.R., Sutter G., Carroll M.W., Yang L.C., Goldstein S., Piatak Jr. M., Elkins W.R., Alvord W.G., Montefiori D.C., Moss B., and Lifson J.D. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70 (1996) 3741-3752
34. Hunter E., and Swanstrom R. Retrovirus envelope glycoproteins. Curr. Top. Microbiol. Immunol. 157 (1990) 187-253
35. Johnston P.B., Dubay J.W., and Hunter E. Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J. Virol. 67 (1993) 3077-3086
36. Kodama T., Wooley D.P., N aidu Y.M., Kestler III H.W., Daniel M.D., Li Y., and Desrosiers R.C. Significance of premature stop codons in env of simian immunodeficiency virus. J. Virol. 63 (1989) 4709-4714
37. Liu M.A., Yasutomi Y., Davies M.-E., Perry H.C., Freed D.C., Letvin N.L., and Shiver J.W. Vaccination of mice and nonhuman primates using HIV-gene-containing DNA. Antibiot. Chemother. 48 (1996) 100-104
38. Mayr A., Hochstein-Mintzel V., and Stickl H. Abstammung, eigenschaften und verwendung des attenuierten vaccinia-stammes MVA (Passage history, properties, and applicability of the attenuated vaccinia virus strain MVA). Infection 3 (1975) 6-14
39. McMichael A.J. HIV vaccines. Annu. Rev. Immunol. 24 (2006) 227-255
40. Men R., Wyatt L., Tokimatsu I., Arakaki S., Shameem G., Elkins R., Chanock R., Moss B., and Lai C.J. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 18 (2000) 3113-3122
41. Meyer H., Sutter G., and Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72 (1991) 1031-1038
42. Mulligan M.J., Yamshchikov G.V., Ritter Jr. G.D., Gao F., Jin M.J., Nail C.D., Spies C.P., Hahn B.H., and Compans R.W. Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types. J. Virol. 66 (1992) 3971-3975
43. Negri D.R.M., Baroncelli S., Michelini Z., Macchia I., Belli R., Catone S., Incitti F., ten Haaft P., Corrias F., Cranage M.P., Polyanskaya N., Norley S., Heeney J., Verani P., and Titti F. Effect of vaccination with recombinant modified vaccinia virus Ankara expressing structural and regulatory genes of SIVmacJ5 on the kinetics of SIV replication in cynomolgus monkeys. J. Med. Primatol. 30 (2001) 197-206
44. Nilsson C., Sutter G., Walther-Jallow L., ten H.P., Akerblom L., Heeney J., Erfle V., Bottiger P., Biberfeld G., and Thorstensson R. Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques. J. Gen. Virol. 83 (2002) 807-818
45. Nussbaum O., Broder C.C., and Berger E.A. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantifying cell fusion-dependent reporter gene activation. J. Virol. 68 (1994) 5411-5422
46. Ourmanov I., Brown C.R., Moss B., Carroll M., Wyatt L., Pletneva L., Goldstein S., Venzon D., and Hirsch V.M. Comparative efficacy of recombinant modified vaccinia virus ankara expressing simian immunodeficiency virus (SIV) gag-Pol and/or env in macaques challenged with pathogenic SIV. J. Virol. 74 (2000) 2740-2751
47. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., Tauer C., Berger R., Barrett N., Jungbauer A., and Katinger H. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 10 (1994) 1651-1658
48. Ritter Jr. G.D., Mulligan M.J., Lydy S.L., and Compans R.W. Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain. Virology 197 (1993) 255-264
49. Rowell J.F., Stanhope P.E., and Siliciano R.F. Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. J. Immunol. 155 (1995) 473-488
50. Spies C.P., and Compans R.W. Effects of cytoplasmic domain length on cell surface expression and syncytium-forming capacity of the simian immunodeficiency virus envelope glycoprotein. Virology 203 (1994) 8-19
51. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H.C., Schäfer H., and Holzner A. MVA-stufenimpfung gegen pocken. klinische erprobung des attenuierten pocken-lebendimpfstoffes, stamm MVA (MVA vaccination against smallpox): clinical trials of an attenuated live vaccinia virus strain (MVA). Dtsch. Med. Wochenschr. 99 (1974) 2386-2392
52. Stittelaar K.J., Wyatt L.S., de Swart R.L., Vos H.W., Groen J., van Amerongen G., van Binnendijk R.S., Rozenblatt S., Moss B., and Osterhaus A. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J. Virol. 74 (2000) 4236-4243
53. Stittelaar K.J., Kuiken T., de Swart R.L., van Amerongen G., Vos H.W., Niesters H.G., van Schalkwijk P., van der Kwast T., Wyatt L.S., Moss B., and Osterhaus A.D. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19 (2001) 3700-3709
54. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10847-10851
55. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., and Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12 (1994) 1032-1040
56. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., and Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70 (1996) 1100-1108
57. Tsujimoto H., Cooper R.W., Kodama T., Fukasawa M., Miura T., Ohta Y., Ishikawa K., Nakai M., Frost E., Roelants G.E., et al. Isolation and characterization of simian immunodeficiency virus from mandrills in Africa and its relationship to other human and simian immunodeficiency viruses. J. Virol. 62 (1988) 4044-4050
58. Veazey R.S., DeMaria M., Chalifoux L.V., Shvetz D.E., Pauley D.R., Knight H.L., Rosenzweig M., Johnson R.P., Desrosiers R.C., and Lackner A.A. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280 (1998) 427-431
59. Vzorov A.N., Lea-Fox D., and Compans R.W. Immunogenicity of full length and truncated SIV envelope proteins. Viral Immunol. 12 (1999) 205-215
60. Wyatt L.S., Shors S.T., Murphy B.R., and Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14 (1996) 1451-1458
61. Wyatt L.S., Carroll M.W., Czerny C.-P., Merchlinsky M., Sisler J.R., and Moss B. Marker rescue of the host range restricted defects of modified vaccinia virus Ankara. Virology 251 (1998) 334-342
62. Wyatt L.S., Whitehead S.S., Venanzi K.A., Murphy B.R., and Moss B. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 18 (1999) 392-397
63. Wyss S., Dimitrov A.S., Baribaud F., Edwards T.G., Blumenthal R., and Hoxie J.A. Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J. Virol. 79 (2005) 12231-12241
64. Zhang Z., Schuler T., Zupancic M., Wietgrefe S., Staskus K.A., Reimann K.A., Reinhart T.A., Rogan M., Cavert W., Miller C.J., Veazey R.S., Notermans D., Little S., Danner S.A., Richman D.D., Havlir D., Wong J., Jordan H.L., Schacker T.W., Racz P., Tenner-Racz K., Letvin N.L., Wolinsky S., and Haase A.T. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286 (1999) 1353-1357
65. Zhu Y.D., Rota P., Wyatt L., Tamin A., Rozenblatt S., Lerche N., Moss B., Bellini W., and McChesney M. Evaluation of recombinant vaccinia virus-measles vaccines in infant rhesus macaques with preexisting measles antibody. Virology 276 (2000) 202-213